May 9, 2013 The Life Sciences Report: Six Superstars for Your Biotech Portfolio by : Tracy Salcedo The Life Sciences Report: The consensus is that biotech is on the upswing and that it may be a safer bet for investors than gold or energy at this point in time. Do you agree? Can you tell[…]

January 9, 2013 Top Picks for 2013 Written By Chloe Lutts Welcome to the super-sized Investment Digest Top Picks for 2013 issue. Inside this issue, you’ll find over 50 of our contributors’ very favorite investments to own this year. Plus, this year we’re bringing you an even wider selection of Top Picks through a collaboration with[…]

November 27, 2012 Isis Pharmaceuticals: Antisense Value by John McCamant, editor The Medical Technology Stock Letter Isis Pharmaceuticals (ISIS) has had a lots of news. The first was the announcement that the company will receive $1.1 million from Alnylam as its portion of the upfront fees from a collaboration with Genzyme. The company also announced that[…]

October 23, 2012 How to Find the Best Biotech Stocks Written By Chloe Lutts Have you ever wondered how to find great biotech stocks in a sea of hopeful but high-risk medical small caps? Well, for my latest Dick Davis Digest contributor interview, I interviewed John McCamant, the editor of a top-performing investment newsletter that’s all about[…]

January 31, 2013 The Life Sciences Report: Watchlist 2013 by George S. Mack Which biotech companies will take off in 2013? To zero in on possible winners, The Life Sciences Report teamed up with Sagient Research to crunch the numbers for companies with potential catalysts on the calendar. The results were sent to experts who, based on their[…]

December 8, 2012 Don’t Be Surprised If Underpriced Small-Cap Biotechs Catch Investors’ Eye Once Again Written By Gene Marcial, Contributor Biotechnology stocks haven’t produced much excitement for investors this year, partly because the Presidential elections and national politics usurped much of the news headlines. So Wall Street and most investors have had little chance or inclination to focus[…]

October 25, 2012 John McCamant on Investing in Blood Cancer Written By George S. Max Hematological cancers present special opportunities for investors.  In this exclusive interview with The Life Sciences Report, John McCamant, editor of the Medical Technology Stock Letter, comments on several companies in the hematology/oncology space, describing the challenges and successes that influence investment in the sector.[…]

October 4, 2012 Pick Biotech Winners Like A Pro: John McCamant Written By George S. Mack John McCamant, editor of the Medical Technology Stock Letter, doesn’t care if a scientist or a businessperson is at the helm of a biotech company, as long as management has skill and broad experience. Investors need to look for companies that[…]

January 17, 2013 Top Picks for 2013 Written By John McCamant Pacira Pharmaceuticals (PCRX) is our top conservative stock recommendation for 2013. The specialty pharmaceutical company develops, commercializes, and manufactures pharmaceutical products for use in hospitals and ambulatory surgery centers. The company’s drugs are based on its proprietary DepoFoam drug delivery technology. Its lead drug, Exparel, is a[…]

Out of the Red and into the Black: John McCamant on Investment in Blood Cancer Companies TICKERS: AMGN, ASTX, CELG, CYCC, DNDN, PCYC, RHHBY October 25, 2012 Source: George S. Mack of The Life Sciences Report Hematological cancers present special opportunities for investors. In this exclusive interview with The Life Sciences Report, John McCamant, editor of the Medical Technology[…]

September 6, 2012 Dizzying gains, stupefying losses in medical tech Commentary: A veteran newsletter repeats its ‘Matterhorn’ pattern Written By Peter Brimelow NEW YORK (MarketWatch) — Medical Technology Stock Letter continues to Matterhorn. What does that say about the market? The long established letter — editor John McCamant is the son of the founding editor,[…]